You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm's influenza testing revenue reached record highs in January and February, and continued at a high level throughout the end of the quarter.
Natera reported $94 million in revenues for the quarter, up from $66.8 million a year ago and beating analysts' consensus estimate of $85 million.
The firm reported that revenues from screening products rose 35 percent year over year to nearly $220 million.
The company posted Q1 revenues of $15.7 million, up from $12.3 million in Q1 2019 and above the consensus Wall Street estimate of $13.3 million.
The firm reported total revenues of $164 million, which was below the consensus Wall Street estimate of $167.2 million.
The San Francisco-based firm reported $64.2 million in revenues, up from $40.6 million a year ago and beating the average Wall Street estimate of $59.4 million.
Asia revenue fell 22 percent year over year, primarily due to a slowdown of testing in China as a result of the COVID-19 pandemic, the company said.
The company's revenue growth was driven by increasing sales of its ePlex molecular diagnostics analyzer, which now has a SARS-CoV-2 test.
The firm's first quarter molecular diagnostics revenues were up 28 percent over Q1 2019 to $45.2 million.
Fulgent saw a 75 percent increase year over year in billable tests, leading to revenues of $7.8 million. It also withdrew its 2020 full-year revenue guidance.